Regeneron Pharmaceuticals Inc (REGN)

Return on total capital

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 4,272,300 4,448,500 4,845,000 4,719,500 4,918,200 6,093,600 6,399,300 9,190,200 9,383,100 8,105,000 7,298,800 4,460,200 3,867,300 3,524,400 3,276,100 2,580,200 2,459,300 2,246,400 2,113,400 2,543,700
Long-term debt US$ in thousands 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300 0
Total stockholders’ equity US$ in thousands 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Return on total capital 15.28% 16.55% 18.63% 18.52% 19.96% 26.02% 28.23% 41.97% 45.22% 42.13% 42.67% 31.96% 29.74% 29.12% 36.17% 21.27% 22.18% 21.39% 21.66% 26.93%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $4,272,300K ÷ ($1,982,900K + $25,973,100K)
= 15.28%

Regeneron Pharmaceuticals, Inc.'s return on total capital has shown a declining trend over the last eight quarters, dropping from 40.26% in Q1 2022 to 14.75% in Q4 2023. This decrease in the return on total capital indicates a reduction in the company's ability to generate profits from the capital invested in its operations. It may suggest challenges in effectively utilizing the company's resources to generate returns for its investors. Further analysis is recommended to identify the underlying factors contributing to this downward trend and to develop strategies to improve the company's return on total capital in the future.


Peer comparison

Dec 31, 2023